

Defining the risk of SARS-CoV-2 variants on immune pr

Nature

605, 640-652

DOI: [10.1038/s41586-022-04690-5](https://doi.org/10.1038/s41586-022-04690-5)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Animal models in SARS-CoV-2 research. <i>Nature Methods</i> , 2022, 19, 392-394.	19.0	51
3	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	4.6	24
4	Mucosal immune responses to infection and vaccination in the respiratory tract. <i>Immunity</i> , 2022, 55, 749-780.	14.3	66
5	PARIS and SPARTA: Finding the Achilles™ Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	2.9	25
6	Bioinformatic and Experimental Analysis of T Cell Immune Reactivity to SARS-CoV-2 and its Variants. <i>Frontiers in Bioinformatics</i> , 2022, 2, .	2.1	6
8	Systems biology of malaria explored with nonhuman primates. <i>Malaria Journal</i> , 2022, 21, .	2.3	11
9	Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	12
10	Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	7
11	Autophagy in health and disease: From molecular mechanisms to therapeutic target. <i>MedComm</i> , 2022, 3, .	7.2	30
14	Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. <i>Nature Communications</i> , 2022, 13, .	12.8	28
15	Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	27
16	Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis – A case report and literature review. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
19	Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1502.	4.4	1
20	From Alpha to omicron: The response of T cells. <i>Current Research in Immunology</i> , 2022, 3, 146-150.	2.8	19
21	Health influence of SARS-CoV-2 (COVID-19) on cancer: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 1395-1405.	2.0	3
22	Malaria vaccine approaches leveraging technologies optimized in the COVID-19 era. <i>Frontiers in Tropical Diseases</i> , 0, 3, .	1.4	1
23	SARS-CoV-2 Monitoring in Wastewater Reveals Novel Variants and Biomarkers of Infection. <i>Viruses</i> , 2022, 14, 2032.	3.3	3
25	Building a Resilient Scientific Network for COVID-19 and Beyond. <i>MBio</i> , 0, , .	4.1	1

#	ARTICLE	IF	CITATIONS
26	Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
28	Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation. <i>Frontiers in Bioinformatics</i> , 0, 2, .	2.1	6
30	Lancemaside A from <i>Codonopsis lanceolata</i> : Studies on Antiviral Activity and Mechanism of Action against SARS-CoV-2 and Its Variants of Concern. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	4
31	Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2022, 3, 100849.	6.5	12
33	Evaluation and comparison of the sensitivity of three commercial RT-qPCR kits used for the detection of SARS-CoV-2 in Santiago, Chile. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	2
34	Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants. <i>Virology Journal</i> , 2022, 19, .	3.4	3
36	Liquid-liquid phase separation of nucleocapsid proteins during SARS-CoV-2 and HIV-1 replication. <i>Cell Reports</i> , 2023, 42, 111968.	6.4	8
37	Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1010970.	4.7	13
38	Potential therapeutic value of necroptosis inhibitor for the treatment of COVID-19. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	5
39	A biophysical model of viral escape from polyclonal antibodies. <i>Virus Evolution</i> , 2022, 8, .	4.9	16
41	Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. <i>BMJ</i> , The, 0, , e072529.	6.0	116
42	Innate Immunity in Cardiovascular Diseasesâ€™ Identification of Novel Molecular Players and Targets. <i>Journal of Clinical Medicine</i> , 2023, 12, 335.	2.4	2
43	Detection of Circulating SARS-CoV-2 Variants of Concern (VOCs) Using a Multiallelic Spectral Genotyping Assay. <i>Life</i> , 2023, 13, 304.	2.4	3
46	A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy. <i>Vaccine</i> , 2023, 41, 2101-2112.	3.8	6
48	mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. <i>Vaccine</i> , 2023, 41, 2439-2446.	3.8	3
49	A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. <i>Cell</i> , 2023, 186, 1263-1278.e20.	28.9	54
50	COVID-19 infection, reinfection, and the transition to endemicity. <i>Lancet</i> , The, 2023, 401, 798-800.	13.7	7
51	Evolution of increased positive charge on the SARS-CoV-2 spike protein may be adaptation to human transmission. <i>IScience</i> , 2023, 26, 106230.	4.1	7

#	ARTICLE	IF	CITATIONS
52	Global landscape of SARS-CoV-2 mutations and conserved regions. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	26
53	Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets. <i>MedComm</i> , 2023, 4, .	7.2	3
54	High Throughput SARS-CoV-2 Genome Sequencing from 384 Respiratory Samples Using the Illumina COVIDSeq Protocol. <i>Genes</i> , 2023, 14, 681.	2.4	2
55	A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. <i>Immunotherapy Advances</i> , 2023, 3, .	3.0	2
56	Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 713.	4.4	3
57	Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. <i>Diagnostics</i> , 2023, 13, 1280.	2.6	0
58	Leveraging deep learning to improve vaccine design. <i>Trends in Immunology</i> , 2023, 44, 333-344.	6.8	3
59	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	7
60	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	46.4	112
61	Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-C3BP1 complex. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	4
62	Multidimensional sample analysis to determine pandemic viral evolution. <i>EBioMedicine</i> , 2023, 92, 104606.	6.1	0
63	Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. <i>EBioMedicine</i> , 2023, 91, 104586.	6.1	6
65	Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	3
66	Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics. <i>JCI Insight</i> , 2023, 8, .	5.0	1
67	Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	12.8	23
69	Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial. , 2023, 2, .		1
70	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. <i>Communications Medicine</i> , 2023, 3, .	4.2	1
72	Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening. <i>Journal of Virology</i> , 2023, 97, .	3.4	1

#	ARTICLE	IF	CITATIONS
73	Availability and use of Standards in vaccine development. <i>Npj Vaccines</i> , 2023, 8, .	6.0	1
74	Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population. <i>EBioMedicine</i> , 2023, 94, 104683.	6.1	4
75	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	6.1	13
76	Containers for computational reproducibility. <i>Nature Reviews Methods Primers</i> , 2023, 3, .	21.2	5
77	SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense. <i>MBio</i> , 0, , .	4.1	1
78	Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate. <i>Vaccine</i> , 2023, 41, 5072-5078.	3.8	2
79	Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. <i>Nature Communications</i> , 2023, 14, .	12.8	6
81	Genomic and Temporal Analysis of Deletions Correlated to qRT-PCR Dropout in N Gene in Alpha, Delta and Omicron Variants. <i>Viruses</i> , 2023, 15, 1630.	3.3	1
82	Trimannose-coupled anti-miR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. <i>Nature Communications</i> , 2023, 14, .	12.8	5
83	Final analysis of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS): a multicenter registry cohort study. , 2023, , .		0
84	Developing brain under renewed attack: viral infection during pregnancy. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
85	Fitness effects of mutations to SARS-CoV-2 proteins. <i>Virus Evolution</i> , 2023, 9, .	4.9	20
86	Artificial intelligence in accelerating vaccine development - current and future perspectives. , 0, 2, .		2
87	Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice. <i>Viral Immunology</i> , 2023, 36, 526-533.	1.3	1
88	Discovery of a Druggable, Cryptic Pocket in SARS-CoV-2 nsp16 Using Allosteric Inhibitors. <i>ACS Infectious Diseases</i> , 2023, 9, 1918-1931.	3.8	1
90	The Retinal Ganglion Cell Repopulation, Stem Cell Transplantation, and Optic Nerve Regeneration Consortium. <i>Ophthalmology Science</i> , 2023, 3, 100390.	2.5	1
92	A spacer design strategy for CRISPR-Cas12f1 with single-nucleotide polymorphism mutation resolution capability and its application in the mutations diagnosis of pathogens. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	0
93	Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection. <i>Vaccines</i> , 2023, 11, 1644.	4.4	1

#	ARTICLE	IF	CITATIONS
94	Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
95	Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	0
96	Assessing airborne transmission risks in COVID-19 hospitals by systematically monitoring SARS-CoV-2 in the air. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	0
99	Deciphering the rule of antigen-antibody amino acid interaction. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
100	Omicron induced distinct immune respiratory transcriptomics signatures compared to pre-existing variants in critically ill COVID-19 patients. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	0
101	Approaches to pandemic prevention – the chromatin vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
102	Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86. <i>Cell Host and Microbe</i> , 2023, , .	11.0	1
103	Interface-Guided Computational Protein Design Reveals Bebtelovimab-Resistance Mutations in SARS-CoV-2 RBD: Correlation with Global Viral Genomes and Bebtelovimab-Escape Mutations. <i>ChemistrySelect</i> , 2023, 8, .	1.5	0
105	The spike-specific TCR ¹ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2024, 22, .	4.4	0
106	Associations of Temporal Cardiometabolic Patterns and Incident SARS-CoV-2 Infection Among U.S. Blood Donors With Serologic Evidence of Vaccination. , 2024, 3, 100186.		0
107	Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters. <i>PLoS Pathogens</i> , 2024, 20, e1011805.	4.7	1
108	Vaccine design via antigen reorientation. <i>Nature Chemical Biology</i> , 0, , .	8.0	3
109	Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket. <i>Acta Crystallographica Section D: Structural Biology</i> , 2024, 80, 123-136.	2.3	0
110	Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. <i>Nature Immunology</i> , 2024, 25, 537-551.	14.5	0
111	Antiviral fibrils of self-assembled peptides with tunable compositions. <i>Nature Communications</i> , 2024, 15, .	12.8	1
112	Cepharanthine analogs mining and genomes of <i>Stephania</i> accelerate anti-coronavirus drug discovery. <i>Nature Communications</i> , 2024, 15, .	12.8	0
113	SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. <i>Immunity</i> , 2024, 57, 587-599.e4.	14.3	0
115	Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2. <i>Nature Communications</i> , 2024, 15, .	12.8	0

#	ARTICLE	IF	CITATIONS
116	Construction and efficacy testing of DNA vaccines containing HLA-A*02:01-restricted SARS-CoV-2 T-cell epitopes predicted by immunoinformatics. Acta Biochimica Et Biophysica Sinica, 2024, , .	2.0	0
117	Genomic Characterization of SARS-CoV-2 Variants from Clinical Isolates during the COVID-19 Epidemic in Mauritania. Genes, 2024, 15, 361.	2.4	0